Anti-LAG3 / CD223 Reference Antibody (relatlimab)

• Catalog Number: orb1806157
• Category: Antibodies
• Description: Anti-LAG3 / CD223 Reference Antibody is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
• Clonality: Monoclonal
• Tested applications: ELISA, FA, FACS, Kinetics
• Reactivity: Human
• Isotype: IgG
• Purity: > 95%
• Conjugation: Unconjugated
• MW: 145.5 kDa
• Target: LAG3 / CD223
• Endotoxins: < 1 EU/mg
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Buffer/Preservatives: 100 mM Pro-Ac 20 mM Arg pH 5.0
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Anti-LAG3 / CD223 Reference Antibody (relatlimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

The purity of Anti-LAG3 / CD223 Reference Antibody (relatlimab)is more than 100% ;determined by SEC-HPLC.

Immobilized human LAG3 His at 2 μg/mL can bind Anti-LAG3 / CD223 Reference Antibody (relatlimab);EC50=0.02812 μg/mL.

Human LAG3 CHO cells were stained with Anti-LAG3 / CD223 Reference Antibody (relatlimab) and negative control protein respectively; washed and then followed by PE and analyzed with FACS; EC78=0.5464 ug/mL.

Relatlimab inhibited the tumor growth of MC38 on Human LAG3 mice. The result showed significant anti-tumor effects; with an tumor inhibition rate (TGI) of 53.8% at 10 mpk at D28.